BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, grade II glioma, grade III glioma, low grade glioma, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-03-13		NCT03749187

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
BeiGene USA, Inc.	2
University of California, San Francisco	637

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital Los Angeles	Los Angeles	United States	226
Children's Hospital of Philadelphia	Philadelphia	United States	434
Dana-Farber Cancer Institute	Boston	United States	626
Duke University Medical Center	Durham	United States	505
Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	United States	238
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center	Hackensack	United States	3
Oregon Health and Science University	Portland	United States	382
St. Jude Children's Research Hospital	Memphis	United States	194
University of California, San Francisco	San Francisco	United States	294
Washington University School of Medicine	St Louis	United States	895
Yale University	New Haven	United States	352